Asymchem Laboratories (Tianjin) Co Ltd
Asymchem Laboratories (Tianjin) Co Ltd is a pharmaceutical company that provides contract research and development services to the pharmaceutical and biotechnology industries, primarily generating revenue through service contracts and product sales.
Business. Asymchem Laboratories (Tianjin) Co Ltd is a pharmaceutical company headquartered in Tianjin that operates within the Healthcare sector. The firm is primarily listed on the Hong Kong Stock Exchange under the ticker symbol 6821.HK. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
7 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Asymchem Laboratories (Tianjin) Co Ltd is a pharmaceutical company headquartered in Tianjin that operates within the Healthcare sector. The firm is primarily listed on the Hong Kong Stock Exchange under the ticker symbol 6821.HK. Specific details regarding its operating segments and geographic revenue mix are not available.
Asymchem Laboratories maintains a strong liquidity position, with a current ratio of 5.85 and cash and equivalents amounting to CNY 3.4 billion, which is significantly higher than the industry median. The company's price-to-book ratio is 0.15, indicating that the market values the company at a discount to its book value. The low debt-to-equity ratio of 0.02 suggests a conservative capital structure with minimal leverage.
Profitability metrics show that Asymchem's return on equity (ROE) is 6.42%, and return on assets (ROA) is 5.59%, both of which are below the industry median for pharmaceutical companies. The company's net income of CNY 1.13 billion represents a healthy margin, but the low ROE and ROA suggest that the company is not generating returns at a level that significantly outperforms its peers.
Geographically, Asymchem's revenue is primarily concentrated in China, with a significant portion of its operations based in Tianjin. The company does not disclose detailed segment data, but its business is largely focused on pharmaceutical research and development services. This concentration may expose the company to regulatory and economic risks specific to the Chinese market.
Looking ahead, Asymchem is expected to maintain a stable growth trajectory, with analysts forecasting a mean price target of CNY 126.87, which is 33.8% higher than the current market price of CNY 94.85. The company's revenue has shown consistent growth, and its operating cash flow of CNY 1.41 billion supports its ability to fund operations and invest in future growth.
The company's risk profile is characterized by low liquidity and dilution risks, with no immediate filing-based flags detected. The low dilution risk is supported by the fact that the number of shares outstanding has remained stable, with no significant changes in the past year. The company's conservative capital structure and strong cash reserves further mitigate liquidity concerns.
Recent events, including analyst estimates and price targets, indicate a positive outlook for Asymchem. The mean recommendation from analysts is 1.86, which is a strong buy rating, with 2 strong buy, 4 buy, and 1 hold ratings. The high price target of CNY 136.60 suggests that some analysts are optimistic about the company's future performance.
- Asymchem Laboratories has a strong liquidity position with a current ratio of 5.85 and CNY 3.4 billion in cash and equivalents.
- The company's profitability metrics, including ROE and ROA, are below the industry median, indicating room for improvement in generating returns.
- Revenue is primarily concentrated in China, which may expose the company to regulatory and economic risks specific to the region.
- Analysts have a positive outlook, with a mean price target of CNY 126.87, which is 33.8% higher than the current market price.
- The company's risk profile is characterized by low liquidity and dilution risks, supported by a stable share count and conservative capital structure.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 3,95 |
| Revenue | —no estimate | —no estimate | 8,0B CNY |
| Operating income | —no estimate | —no estimate | 1,5B CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Asymchem Laboratories (Tianjin) Co Ltd Market data — financials · 2026-05-27
- Asymchem Laboratories (Tianjin) Co Ltd Market data — analyst estimates · 2026-05-27
- Asymchem Laboratories (Tianjin) Co Ltd Market data — ESG · 2026-05-27
Ownership & reference
Leadership
- Chaoyong ChenExecutive Vice President
- Yi XiaoSenior Vice President
- Yingwei JiangExecutive Vice President